Lipase Reagent Market Analysis by Type (Turbidity Method, and Colorimetric Method); by Application (Hospitals, Clinics, and Others); and by Indication (Pancreatic Disorders, Cancer, and Cystic Fibrosis) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now Report ID: 4247 | Published Date: Feb 23, 2023
The global lipase reagent market is estimated to garner a revenue of ~USD 1521 Billion by the end of 2035 by growing at a CAGR of ~7% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of ~USD 631 Billion in the year 2022. The growth of the market can be attributed to the increasing number of patients who are suffering from different diseases that require lipase analysis. The lipase testing reagents act as indicators to study the presence of pancreas-related disorders and other gastric problems. The rise in widespread demand for lipase testing reagents on account of indigestion, acute and chronic pancreatic disorders, gastroesophageal reflux disease (GERD), and other intestinal disorders is expected to drive the market growth during the forecast period. The incidence of acute pancreatitis raised from 28 per 100,000 population in 1999 to 36 per 100,000 population in 2010.
In addition to these, factors that are believed to fuel the market growth of Lipase Reagent include the increase in diseases like vitamin deficiency, dehydration, malnutrition, high gastric acids, and persistent diarrhea. As per the Centers for Disease Control and Prevention, the number of adults diagnosed with ulcers was about 14.8 million in 2018.
Besides, the demand for lipase testing reagents market is propelling as children with cystic fibrosis (CF) or Schwachman-Diamond Syndrome (SDS) diagnosis increase. Lipase levels are high in patients with cystic fibrosis. According to the World Gastroenterology Organization, out of 100%, 49% of females and 36.6% of males have the most common disorders like constipation, diarrhea, IBS, proctalgia fungal, and dyspepsia at rates of 11.7%, 4.7%, 4.1%, 5.9%, and 7.2% respectively.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~7% |
|
Base Year Market Size (2022) |
~ USD 631 Billion |
|
Forecast Year Market Size (2035) |
~ USD 1521 Billion |
|
Regional Scope |
|
Growth Drivers
Increasing Diarrhea Cases in Children- Globally, 1.7 billion children are affected with diarrhea disease every year according to the World Health Organization.
Rising Concern for Diagnosis – The accurate detection of several medical disorders that might be suggested by increased levels of lipase in the body is a rising issue. For these kinds of illnesses to be effectively treated and managed, a fast and accurate diagnosis is crucial. The primary diagnosis at office visits for all digestive diseases was stated to be 36.6 million in the year 2010 in the U.S.
Government Initiatives in the Healthcare Sector –The Universal Health Coverage progress rate is projected to cover health services to 290 million by 2023, compared to the baseline value of 2018 leaving a difference of 710 million to reach the target.
Poor Lifestyle and Nutritional Deficiency – Elevated lipase levels and other metabolic abnormalities can be caused by a poor lifestyle and dietary deficits. As per the Food and Agriculture Organization of the United Nations, it is estimated that between 720 to 811 million individuals faced hunger worldwide in 2020.
Lack of Sanitation Knowledge and the Unhygienic Environment– As of 2021 among 3.6 billion people, only 1.9 billion people are living with basic sanitation services and 494 million go for open defecation. Moreover, the population growth is also leading to higher demand for sanitation services, which is further anticipated to boost the market growth. The world population raised from about 1 billion in 1800 to 7.9 billion in 2019.
Challenges
The global lipase reagent market is segmented and analyzed for demand and supply by application into hospitals, clinics & others, out of which, the hospital segment is anticipated to hold the largest market size by the end of 2035. The market is estimated to grow on account of expanding healthcare sector and advancements in technology within the medical sector for diagnostics and therapeutics. As per estimations of the Organization for Economic Co-operation and Development (OECD), health expenditure raised by 5% from 8.8% GDP in 2019 to 9.7% GDP in 2020 across OECD countries.
The global lipase reagent market is also segmented and analyzed for demand and supply by indication into pancreatic disorders, cancer, and cystic fibrosis. Out of these segments, the pancreatic disorders segment is projected to garner the highest market revenue by the end of 2035. The segment is growing on the fact that most cases of high lipase levels indicate a problem with the pancreas. For pancreatic illnesses to be effectively treated and managed, an accurate and fast diagnosis is essential, and measuring lipase levels can be a key step in this process. For instance, it was found that about 45 to 350 in million people suffer from acute pancreatitis in the U.S.
Our in-depth analysis of the global lipase reagent market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Indication |
|
The North American lipase reagent is projected to hold the largest market share by the end of 2035, on the back of increasing concern among people about complications related to the gastrointestinal tract. Among 440 million non-cancer medical conditions, over 22 million acute digestive conditions with 11 million gastroenteritis and 6 million indigestion cases are reported. Besides, the North American region is having good infrastructure and more hospitals propelling the growth of the global lipase reagent market during the forecast period. According to the American Hospital Association, the total number of all hospitals in the North American region is 6,000 with staffed beds of 920,000 in 2022. Also, the regional government policies towards public health care programs attribute to the growth of the market.
Moreover, the Asia Pacific lipase reagent market is also growing at a fast rate, owing to the rising demand for lipase reagents in the pharma, food and beverage, and biotech sectors. The need for lipase reagents for use in developing drugs, biomarker identification, and bioprocessing applications is rising as a result of the rapidly developing biotechnology and pharmaceutical sectors. The requirement for lipase reagents in the detection and treatment of lifestyle-related disorders like diabetes and obesity is rising as their prevalence rises. The need for lipase reagents for use in food evaluation and quality control is also rising as a result of the region's expanding food and beverage industries, notably in nations like China and India.
AzuR: announced a positive result of MS1819 during phase 2 trials, by assessing MS1819 along with porcine-derived pancreatic enzyme replacement therapy for treating severe exocrine pancreatic insufficiency in patients with cystic fibrosis.
DiaSysDiagnostic Systems GmH announced the development of Lipase DC FS, a state-of-the-art direct colorimetric assay, with improved stability for Pancreatic Diagnosis.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Increasing gastrointestinal issues and rising concern for diagnosis are the major factors driving the growth of the lipase reagent market.
Ans: The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2035.
Ans: Lack of a proper healthcare system in low-income regions and less awareness of the diagnosis and gastric issues are the challenges affecting the market growth.
Ans: The market in North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market DIALAB, DiaSys Diagnostic Systems GmbH, Sunson Industry Group Co.,Ltd, Randox Laboratories Ltd., Abbott, Beckman Coulter, Inc., Biocompare, VitroScient, Merck Group, Sisco Research Laboratories Pvt. Ltd. BioSystems.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, application, indication, and by region.
Ans: The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
